Zenas BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZBIO Nasdaq 2836 zenasbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zenas BioPharma, Inc.

The Bull Case For Royalty Pharma (RPRX) Could Change Following $2 Billion Debt Raise and New Royalty Deals - Nov 2nd, 2025 6:12 am
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks - Oct 31st, 2025 10:41 am
Zenas’ bifunctional mAb scores at Phase II in relapsing MS - Oct 28th, 2025 6:35 am
Incyte trims pipeline; Zenas surges on MS drug results - Oct 28th, 2025 4:00 am
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis - Oct 27th, 2025 5:05 am
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Oct 10th, 2025 10:16 am
Zenas BioPharma Granted License for MS Drug Candidate in $2 Billion Deal - Oct 8th, 2025 3:42 am
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - Oct 8th, 2025 3:00 am
Bullish Zenas BioPharma Insiders Loaded Up On US$1.11m Of Stock - Sep 30th, 2025 6:51 am
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - Sep 2nd, 2025 5:15 am
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - Sep 2nd, 2025 5:05 am
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - Aug 26th, 2025 5:05 am
We Think Zenas BioPharma (NASDAQ:ZBIO) Needs To Drive Business Growth Carefully - Aug 20th, 2025 6:28 am
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - Aug 12th, 2025 5:05 am
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jun 20th, 2025 2:15 pm
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference - May 29th, 2025 5:05 am
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates - May 15th, 2025 5:05 am
Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase - Apr 23rd, 2025 6:27 am
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 17th, 2025 2:20 pm
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer - Apr 7th, 2025 5:05 am